



PRESS RELEASE

Active Biotech Capital Markets Day

Lund, Sweden, June 10, 2010 - Today, Active Biotech AB (NASDAQ OMX Nordic: ACTI) is holding a capital markets day for analysts, investors and media at IVA Conference Center in Stockholm. An update on the company's project portfolio will be given as well as a more in depth presentation of the TASQ prostate cancer project and proposed Phase III outline. The agenda for the day is as follows:

Time (CEST)

14:00 – 14:05	Welcome and introduction	Tomas Leanderson
14:05 – 14:40	Project portfolio	Tomas Leanderson
14:40 – 14:45	Q & A	
14:45 – 15:25	TASQ Phase II	Göran Forsberg
15:25 – 15:35	Q & A	
15:35 – 15:45	TASQ Phase III outline	Tomas Leanderson
15:45 – 15:55	Active Biotech going forward	Tomas Leanderson
15:55 – 16:00	Q & A	

The Capital Markets Day will also be available to follow via Active Biotech's website from 14:00 CEST at www.activebiotech.com.

Active Biotech AB (publ)

Tomas Leanderson
President and CEO

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit www.activebiotech.com for more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on June 10, 2010.